Compare TDC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDC | MLYS |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2007 | 2023 |
| Metric | TDC | MLYS |
|---|---|---|
| Price | $28.44 | $24.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $34.78 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.38 | ★ 37.43 |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,156,000,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.44 | N/A |
| P/E Ratio | $7.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.33 | $22.30 |
| 52 Week High | $41.78 | $47.65 |
| Indicator | TDC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 37.90 |
| Support Level | $25.99 | $22.36 |
| Resistance Level | $29.51 | $31.36 |
| Average True Range (ATR) | 0.90 | 1.44 |
| MACD | 0.00 | -0.45 |
| Stochastic Oscillator | 39.75 | 2.90 |
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.